Moving forward with dolutegravir in children weighing less than 20 kg

Lancet HIV. 2022 May;9(5):e301-e302. doi: 10.1016/S2352-3018(22)00062-5.

Authors

Helena Rabie¹, Juanita Lishman², Lisa Jane Frigati²

Affiliations

¹ Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Faculty of medicine and Health Sciences, Parrow, Cape Town, 7505, South Africa. Electronic address: [email protected].
² Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Faculty of medicine and Health Sciences, Parrow, Cape Town, 7505, South Africa.

PMID: 35489373
DOI: 10.1016/S2352-3018(22)00062-5

No abstract available

Publication types

Comment

MeSH terms

Child
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Oxazines
Piperazines
Pyridones

Substances

Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir